Lexeo Therapeutics, Inc.
LXEO
$4.85
$0.1853.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 27.57% | 44.03% | 39.45% | 13.55% | 6.13% |
| Gross Profit | -27.57% | -44.03% | -39.45% | -13.55% | -7.17% |
| SG&A Expenses | 104.43% | 103.00% | 105.92% | 136.75% | 101.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.35% | 60.36% | 54.38% | 35.82% | 23.49% |
| Operating Income | -50.35% | -60.36% | -54.38% | -35.82% | -24.48% |
| Income Before Tax | -47.86% | -57.46% | -48.11% | -29.67% | -21.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.86% | -57.46% | -48.11% | -29.67% | -21.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.86% | -57.46% | -48.11% | -29.67% | -21.16% |
| EBIT | -50.35% | -60.36% | -54.38% | -35.82% | -24.48% |
| EBITDA | -50.76% | -60.85% | -54.76% | -36.03% | -24.41% |
| EPS Basic | 77.73% | 85.18% | 90.65% | 92.28% | 62.58% |
| Normalized Basic EPS | 77.20% | 85.18% | 90.65% | 92.28% | 62.58% |
| EPS Diluted | 77.73% | 85.18% | 90.65% | 92.28% | 62.58% |
| Normalized Diluted EPS | 77.20% | 85.18% | 90.65% | 92.28% | 62.58% |
| Average Basic Shares Outstanding | 80.69% | 177.47% | 496.95% | 1,599.32% | 1,112.74% |
| Average Diluted Shares Outstanding | 80.69% | 177.47% | 496.95% | 1,599.32% | 1,112.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |